COMMUNIQUÉS West-GlobeNewswire

EvolveImmune Therapeutics to Present Update on Lead Asset EVOLVE104 and New Data for EVOLVE T Cell Engager Platform at 2026 AACR Annual Meeting
14/04/2026
Poster Presentation to Spotlight Ongoing Phase 1 Clinical Trial of EVOLVE104 Oral and Poster Presentations to Highlight Preclinical Data Demonstrating Ability of EVOLVE Platform to Drive Enhanced T Cell Activity through [...]
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14/04/2026
BEDFORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today [...]
Cannara Reports Q2 Fiscal 2026 Results with Continued Profitability, Strong Operating Cash Flow and #1 Retail Market Share in Québec
14/04/2026
Delivered strong Q2 financial results: Generated $27.2 million in total net revenues, $11.6 million in gross profit before fair value adjustments or 43% of revenues, $6.0 million in adjusted EBITDA 1 , and $2.9 million [...]
Cannara publie ses résultats du second trimestre de l'exercice 2026 : rentabilité soutenue, solide flux de trésorerie d'exploitation et première place en termes de part de marché au détail au Québec
14/04/2026
De solides résultats financiers au second trimestre : 27,2 millions de dollars de produits totaux net, déduction faite des taxes d’accise, 11,6 millions de dollars de marge brute avant ajustements de la juste valeur ( [...]
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
14/04/2026
BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal [...]
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
14/04/2026
FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026 ( [...]
Trained Therapeutix Discovery’s Chief Scientific Officer, Dr. Mulder, Honored with Fellowship at the American Institute for Medical and Biological Engineering (AIMBE)
14/04/2026
-Recognition highlights pioneering contributions to nanomedicine underpinning the company’s RIDE platform OSS, The Netherlands, April 14, 2026 (GLOBE NEWSWIRE) -- Trained Therapeutix Discovery, a biotechnology company [...]
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
14/04/2026
SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel [...]
Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
14/04/2026
ALACHUA, Fla. and TAMPA, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
VitalHub Announces Novari Health Referral Central Intake Implementation in Ontario
14/04/2026
TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that Novari Health (“Novari”), a VitalHub company, has executed a multi-year agreement [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
14/04/2026
Company Announcement Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc [...]
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences
14/04/2026
Dr. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13 - 16) and the Needham Virtual Psychedelics Forum (April 27) [...]
Greenwich LifeSciences Provides Update on Financing Strategy
14/04/2026
STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
14/04/2026
Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026 QUVIVIQ® is approved through Taiwan’s Streamlined Review [...]
Transactions in connection with share buy-back program
14/04/2026
Company announcement no. 10 - 26 14 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting
14/04/2026
MST-0312 is a FAP-targeted lymphotoxin beta receptor (LTBR) agonist bispecific antibody designed to induce tertiary lymphoid structures for the treatment of solid tumors CAMBRIDGE, United Kingdom, April 14, 2026 (GLOBE [...]
Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development
14/04/2026
Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 clinical development AT-108 is a transformative immunotherapy that triggers a personalized [...]
PannTheraPi Announces Significant Clinical Development and Strategic Milestones
14/04/2026
Regulatory submission filed to initiate a Phase 2a trial of its drug candidate, PTI5803 in patients with focal cortical dysplasia (FCD), a rare and severe form of epilepsy PannTheraPi secures European patent covering [...]
PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique
14/04/2026
PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique Le dépôt du dossier réglementaire pour l’initiation de l’essai clinique de Phase 2a évaluant son candidat médicament, PTI5803, [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum